




PHARMACEUTICAL 2021









The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 149% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	5,228
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	217
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	3.7
Other Liabilities	0
Other Net Income	5.2
Other Revenues	0
Property and Equipment	0
Research and Development	1,224
Selling, General and Administrative Expense	2,043

Output Variable	Value in 1000 USD
Assets	5,228
Liabilities	217
Expenses	3,270
Revenues	0
Stockholders Equity	5,012
Net Income	-3,265
Comprehensive Net Income	-3,265
Economic Capital Ratio	197%

